MAYNE CONTINUES DEVELOPMENT OF PLIVA G-CSF

PLIVA, headquartered at Croatia, has finalized an agreement with Mayne Pharma of Australia, for the continued development of biosimilar granulocyte-colony stimulating factor (G-CSF) for the European, South East Asian, Middle Eastern and Asia Pacific markets.

BioSpectrum (http://www.biospectrumasia.com/content/280706AUS1235.asp)